Maschoff Brennan’s technology transactions team helps clients negotiate the maze of legal and commercial issues that arise in connection with the acquisition, development, adoption, product commercialization, and licensing of new technologies and intellectual property assets in a wide range of industries.
Clients turn to us for focused guidance on the IP, technology, privacy, and data security related aspects of their business transactions — from research and development of new technologies, asset commercialization, complex carve-outs, to the everyday reality of doing business in a global and networked world. We advise clients on their most important technology and IP-related contracts, mergers and acquisitions, joint ventures, joint development agreements, strategic alliances, customer agreements, and website policies and terms of service. We also assist our clients to help them to develop secure and compliant platforms, websites, ecommerce platforms, and products, and assist clients in realizing the maximum value of their data and IP assets.
Our team provides strategic guidance and representation to the world’s leading corporations and consumer brands, financial institutions, platforms, and emerging technology companies on the full range of transactions and the regulation of technology and data. Our lawyers help companies negotiate their key software and information technology licensing and procurement, patent licensing and monetization, collaboration, outsourcing and cloud agreements, and provide practical and business-focused legal advice on important development and distribution deals across industries and market sectors.
Our support for technology transactions continues beyond the initial transaction. We advise our clients on successfully managing long-term relationships with suppliers, ensure compliance with U.S. and international data privacy, consumer protection, trade, and products liability requirements and laws, implementing sustainable governance models, and resolving disputes. Our lawyers focus on offering practical advice that enables our clients to balance compliance to optimize business relationships with customers and consumers going forward and achieve value and cost savings.
Technology Transfer and Higher Education Representation
Maschoff Brennan has significant experience advising universities, colleges, and other higher education institutions on the legal and commercial issues surrounding technology transfer and research commercialization. We work closely with technology transfer offices, research administrators, and university leadership to help move academic innovation from the lab to the marketplace while protecting institutional interests and complying with applicable legal and regulatory requirements.
We regularly serve as a strategic bridge between academic institutions and industry partners, helping align university research objectives with the commercial, operational, and regulatory priorities of startups, established companies, and investors. Our attorneys understand both sides of these relationships and help structure collaborations that facilitate innovation, accelerate commercialization, and support long-term partnerships.
Our team advises on the full lifecycle of university-generated intellectual property, including sponsored research agreements, industry collaborations, joint development arrangements, option and license agreements, startup formation, and equity participation structures. We frequently negotiate licenses with startups and established companies across a wide range of technologies, including life sciences, medical devices, software, and advanced engineering.
We also counsel higher education clients on compliance with federal funding and research obligations, including Bayh-Dole considerations, export controls, data rights, and publication rights, as well as ongoing management of licensed technologies and post-license enforcement issues. Drawing on our broader experience in technology transactions, IP, and regulatory counseling, we help institutions balance academic missions, commercialization goals, and risk management while maximizing the value and impact of their research portfolios.